Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
05:00am, Thursday, 07'th Dec 2023
These companies all have solid histories of dividend increases and are making future dividend payments a priority. You can likely count on them to grow your passive income from year to year.
Cerevel options trading surge before AbbVie deal news raises eyebrows
10:33pm, Wednesday, 06'th Dec 2023
Trading in the options of Cerevel Therapeutics Holdings Inc experienced an unusual surge along with its stock price in the days before Wednesday's announcement that AbbVie would buy the drug developer
AbbVie to buy drug developer Cerevel for $8.7 billion
06:24pm, Wednesday, 06'th Dec 2023
AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its huge-selling arthritis drug Hum
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion
05:06pm, Wednesday, 06'th Dec 2023
The deal is AbbVie's latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic competition.
AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal
04:59pm, Wednesday, 06'th Dec 2023
AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel's “robust” neuroscience pipeline adds medications that may transform s
7 High-Dividend Stocks to Buy for a Lifetime of Passive Income
04:21pm, Wednesday, 06'th Dec 2023
As investors, we always strive to build a well-balanced portfolio that can provide stability through various economic cycles. While high-flying growth stocks generate all the hype these days (and dese
Exclusive: AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources
04:08pm, Wednesday, 06'th Dec 2023
AbbVie Inc is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc , a developer of drugs for neurological conditions such as Parkinson's, people familiar with the mat
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:31am, Tuesday, 05'th Dec 2023
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition
05:00pm, Sunday, 03'rd Dec 2023
AbbVie has agreed to acquire ImmunoGen for $10 billion, nearly double its previous trading price. The acquisition provides AbbVie with a commercial-stage company and a flagship drug that generated $10
These biotechs targeting multiple neurodegenerative diseases
08:15am, Friday, 01'st Dec 2023
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion
07:31am, Friday, 01'st Dec 2023
AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.
Abbvie's $10bn swoop puts the spotlight on antibody-drug conjugates stocks
03:40am, Friday, 01'st Dec 2023
AbbVie Inc has announced the acquisition of ImmunoGen (NASDAQ:IMGN) for $10.1 billion in cash - a deal that takes into the world of antibody-drug conjugates (ADC), which target cancer cells more pre
Why Abbvie Stock Popped Today
07:19pm, Thursday, 30'th Nov 2023
The pharmaceutical sector veteran announced its latest major asset buy. It has agreed to purchase one of its peers.
This Combination of 3 Stocks Provides Monthly Income
05:17pm, Thursday, 30'th Nov 2023
Receiving steady dividend payouts is always a great feeling, as paydays are always the best. Of course, most dividends are paid quarterly.
AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study
01:32pm, Thursday, 30'th Nov 2023
Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.
